이 유전자는 스테로이드, 빌리루빈, 호르몬, 약물 등 작은 지방질 분자를 수용성, 배설성 대사물로 변형시키는 글루쿠로니드화 경로의 효소인 UDP-글루쿠로노실전달효소를 인코딩한다. 이 유전자는 여러 UDP-글루쿠로노실 전이를 암호화하는 복잡한 위치의 일부다. 로커스는 13개의 독특한 첫 번째 엑손과 4개의 공통 엑손들을 포함한다. 다른 첫 번째 엑손 중 4개는 유사 유전자로 간주된다. 나머지 9개의 5인치 엑손은 각각 4개의 공통 엑손에 쪼개져 서로 다른 N-termini와 동일한 C-termini를 가진 9개의 단백질이 생성될 수 있다. 각 첫 번째 엑손은 기판 결합 사이트를 암호화하고, 자체 프로모터에 의해 규제된다. 이 유전자에 의해 인코딩된 효소는 페놀에 활발히 작용한다.[7]
Prausa SE, Fukuda T, Maseck D, et al. (2009). "UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients". Clin. Pharmacol. Ther. 85 (5): 495–500. doi:10.1038/clpt.2009.3. PMID19225446. S2CID33309241.
Ross CJ, Katzov-Eckert H, Dubé MP, et al. (2009). "Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy". Nat. Genet. 41 (12): 1345–9. doi:10.1038/ng.478. PMID19898482. S2CID21293339.
Korprasertthaworn P, Udomuksorn W, Yoovathaworn K (2009). "Three novel single nucleotide polymorphisms of UGT1A9 in a Thai population". Drug Metab. Pharmacokinet. 24 (5): 482–5. doi:10.2133/dmpk.24.482. PMID19881262.
van Schaik RH, van Agteren M, de Fijter JW, et al. (2009). "UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients". Clin. Pharmacol. Ther. 86 (3): 319–27. doi:10.1038/clpt.2009.83. PMID19494809. S2CID21082902.
Sánchez-Fructuoso AI, Maestro ML, Calvo N, et al. (2009). "The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients". Transplant. Proc. 41 (6): 2313–6. doi:10.1016/j.transproceed.2009.06.038. PMID19715905.
Chu XY, Liang Y, Cai X, et al. (2009). "Metabolism and renal elimination of gaboxadol in humans: role of UDP-glucuronosyltransferases and transporters". Pharm. Res. 26 (2): 459–68. doi:10.1007/s11095-008-9799-5. PMID19082692. S2CID24490597.
Bock KW, Gschaidmeier H, Heel H, et al. (1999). "Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyltransferases". Drug Metab. Rev. 31 (2): 411–22. doi:10.1081/DMR-100101927. PMID10335444.
Saito Y, Sai K, Maekawa K, et al. (2009). "Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese". Drug Metab. Dispos. 37 (2): 272–6. doi:10.1124/dmd.108.024208. PMID18981166. S2CID2886803.
Ménard V, Girard H, Harvey M, et al. (2009). "Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population". Hum. Mutat. 30 (4): 677–87. doi:10.1002/humu.20946. PMID19204906. S2CID6235077.
Cecchin E, Innocenti F, D'Andrea M, et al. (2009). "Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan". J. Clin. Oncol. 27 (15): 2457–65. doi:10.1200/JCO.2008.19.0314. PMID19364970.
Fujiwara R, Nakajima M, Yamamoto T, et al. (2009). "In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9". Drug Metab. Pharmacokinet. 24 (3): 235–44. doi:10.2133/dmpk.24.235. PMID19571435.
Kadakol A, Ghosh SS, Sappal BS, et al. (2000). "Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype". Hum. Mutat. 16 (4): 297–306. doi:10.1002/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z. PMID11013440.